Antibodies decline but blueprint remains

2,275 Views | 7 Replies | Last: 5 yr ago by JWAggie1991
jsdaltxag
How long do you want to ignore this user?
I've heard the last couple of days that they are seeing the antibodies decline over time, but today someone mentioned that the body still has the blueprint to rapidly produce antibodies once the virus is detected again by the body.

Can any of the docs confirm this? Has there been documentation of someone that has had it, come down with it again?
BTMTAT
How long do you want to ignore this user?
AG
https://en.m.wikipedia.org/wiki/Memory_B_cell
Cepe
How long do you want to ignore this user?
AG
Just like the common cold virus that is caused by the coronavirus strains you can get a cold again. But, you typically don't get a cold right after having a cold. There is usually a period of time before. Some colds hit you worse than others.

This new virus is similar except we haven't been exposed to it before. As the population is exposed to it our bodies will be better and better at handling it.

This is the way my simple mind thinks about it. . . .
Complete Idiot
How long do you want to ignore this user?
Immune system 101
Dad
How long do you want to ignore this user?
AG
This is just my guess, but I think our bodies will handle it better after the first time. That may mean we don't get sick or that we get less sick, but I don't see people getting it in 2020 and then dying or ending up in the hospital from it when exposed again in 2021.
greg.w.h
How long do you want to ignore this user?
AG
This is the article I read. Was surprised by the mention of T-helper cells with memory.

https://www.sciencemag.org/news/2020/05/t-cells-found-covid-19-patients-bode-well-long-term-immunity
BusterAg
How long do you want to ignore this user?
AG
Great study out in nature today: https://www.nature.com/articles/s41586-020-2550-z
It takes a special kind of brainwashed useful idiot to politically defend government fraud, waste, and abuse.
RandyAg98
How long do you want to ignore this user?
AG
Abstract for that paper. Fascinating stuff.

Quote:

Abstract

Memory T cells induced by previous pathogens can shape the susceptibility to, and clinical severity of, subsequent infections1. Little is known about the presence of pre-existing memory T cells in humans with the potential to recognize SARS-CoV-2.

Here, we first studied T cell responses to structural (nucleocapsid protein, NP) and non-structural (NSP-7 and NSP13 of ORF1) regions of SARS-CoV-2 in COVID-19 convalescents (n=36). In all of them we demonstrated the presence of CD4 and CD8 T cells recognizing multiple regions of the NP protein. We then showed that SARS-recovered patients (n=23) still possess long-lasting memory T cells reactive to SARS-NP 17 years after the 2003 outbreak, which displayed robust cross-reactivity to SARS-CoV-2 NP.

Surprisingly, we also frequently detected SARS-CoV-2 specific T cells in individuals with no history of SARS, COVID-19 or contact with SARS/COVID-19 patients (n=37). SARS-CoV-2 T cells in uninfected donors exhibited a different pattern of immunodominance, frequently targeting the ORF-1-coded proteins NSP7 and 13 as well as the NP structural protein. Epitope characterization of NSP7-specific T cells showed recognition of protein fragments with low homology to "common cold" human coronaviruses but conserved amongst animal betacoranaviruses. Thus, infection with betacoronaviruses induces multispecific and long-lasting T cell immunity to the structural protein NP.

Understanding how pre-existing NP- and ORF-1-specific T cells present in the general population impact susceptibility and pathogenesis of SARS-CoV-2 infection is of paramount importance for the management of the current COVID-19 pandemic.
JWAggie1991
How long do you want to ignore this user?
AG
I tested positive and am in a clinical study for antibodies so not sure if anyone really knows
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.